FDA Letter API

7 Daze, LLC

Letter data

Company
7 Daze, LLC
Recipient
7 Daze, LLC | United States
Issue date
2018-07-31
Posted date
Not available
FDA office
United States
Subject
Not available
Product
Tobacco
CMS ID
Not available
Reference number
Not available
FEI
Not available
Inspection dates
2018-07-19 to 2018-07-25

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER 7 Daze, LLC July 31, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Tobacco Recipient: 7 Daze, LLC United States Issuing Office: United States Center for Tobacco Products 10903 New Hampshire Avenue Silver Spring, MD 20993 JULY 31, 2018 VIA UPS and Electronic Mail John Lau 7 Daze, LLC 13170 Spring Street Baldwin Park, CA  91706 info@7dazemfg.com RE: Warning Letter issued to 7 Daze, LLC (RW1800845) Dear John Lau: On May 1, 2018, the United States Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Pink Sticks e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your Pink Sticks e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children. On July 11, 2018, July 17, 2018, and July 23, 2018, you sent FDA a response to the Warning Letter, and we held teleconferences on July 19, 2018 and July 25, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violations identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violation identified in the Warning Letter. We note that you may have other tobacco products with labeling and/or advertising that causes the product to be misbranded for similar reasons to those discussed above. You are responsible for taking any necessary actions to bring your tobacco products into compliance with the requirements of the law. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov . Sincerely, /S/ Ele Ibarra-Pratt Division Director Office of Compliance and Enforcement Center for Tobacco Products VIA UPS and Electronic Mail cc: John Lau 7 Daze LLC 7629 Garvalia Avenue Rosemead, CA 91770-3064 WhoIsGuard Inc. 64c7f9a8745c4e2a9391e089a1fbe8ab.protect@whoisguard.com NameCheap Inc. abuse@namecheap.com Shopify Inc. abuse@shopify.com Content current as of: 08/23/2018 Regulated Product(s) Tobacco